NCT06035016View on ClinicalTrials.gov

Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer

RecruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

June 1, 2027

Study Completion Date

June 1, 2027

Conditions
HER2-positive Breast CancerEarly-stage Breast Cancer
Interventions
DRUG

pyrotinib combined with Capecitabine

Pyrotinib 400mg, qd, po, day 1-21, q3w, Capecitabine 1000mg/m2, bid po d1-14, q3w

DRUG

treatment of physician's choice

Treatment of physician's choice

Trial Locations (1)

100032

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER